Dr. Siddhartha Harish Krishna Devarakonda, MD

Dr. Devarakonda practices at Swedish Medical Center -First Hill in Seattle, Washington.

Dr. Devarakonda's NPI, 1487932398, was assigned on July 26, 2011. Dr. Devarakonda holds Washington license MD61372698.

Dr. Devarakonda's primary practice is Swedish Medical Center -First Hill, at 747 Broadway, Seattle, WA 98122 in King County. The practice phone is (206) 386-6000.

Dr. Devarakonda's primary practice is Swedish Medical Center -First Hill in Seattle, Washington. Dr. Devarakonda is also affiliated with Swedish First Hill Campus. The medical group on file is Swedish Health Services. Dmand AI also links Dr. Devarakonda to 4 more hospitals, 1 group practice or clinic and 1 medical group, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Devarakonda practices, 6 sites in all. Vendor and product names are available with a free account.

Medical oncology is Dr. Devarakonda's primary specialty in the NPI Registry, under taxonomy code 207RX0202X. Dmand AI has Dr. Devarakonda's licenses on file in 2 states: Washington and Missouri.

CMS data shows 774 Medicare services from Dr. Devarakonda across 7 procedure codes in 2024, for 114 Medicare patients. Medicare paid $59,680 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 114 Medicare patients who saw Dr. Devarakonda in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have cancer, and 68% have high blood pressure. 13% are also on Medicaid. Their average risk score is 2.17, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Devarakonda's median patient age at 73, with 62% women.

In 2024, Dr. Devarakonda wrote 771 Medicare Part D claims for 99 patients. 60% of them were for generic drugs. CMS names the drug for 585 of them, across 18 drugs with 11 or more claims each, at $3,747,172 in total drug cost. In 2023, CMS named 137 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Devarakonda for performance year 2024, reported as part of a group. Dr. Devarakonda accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Devarakonda as offering telehealth.

Dmand AI links 48 papers to Dr. Devarakonda, published from 2011 to 2024. 2022 was the busiest year, with 8. The most frequent topics are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung and Genome, Human. Dr. Devarakonda has published most often in Clin Lung Cancer. Dr. Devarakonda's most frequent co-authors are Daniel Morgensztern, MD, Saiama Naheed Waqar, MD and Jeffrey Peter Ward, MD.

Dmand AI links Dr. Devarakonda to 11 clinical trials, 5 of them phase 2 studies. 7 are still active or recruiting. Conditions studied include Carcinoma, Bronchogenic, Small Cell Lung Carcinoma and Carcinoma, Non-Small-Cell Lung. Washington University School of Medicine sponsors the most, 6. Open Payments lists research payments to Dr. Devarakonda that name 1 trial.

CMS Open Payments shows 224 general payments to Dr. Devarakonda from 17 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 48% of the total. AstraZeneca Pharmaceuticals LP paid the most, $82,651. It also lists 3 research payments totaling $22,550 from 2019 to 2020, naming 1 clinical trial.